TICKERNERD
Menu
MAZEMAZEHealthcare · Biotechnology

MAZE Stock Forecast: Maze Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$33
+3.50% on the day

The 14 Wall Street analysts covering Maze Therapeutics, Inc. hold a median 12-month price target of $55 — +64.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 4 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.8B
Ticker Nerd rank
31/ 100
Median analyst target
$55
Analysts covering
14
Revenue$0.0
Operating income−$48.0M
Net income−$44.7M
Free cash flow−$15.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.2%
1M
+26.3%
YTD
−19.4%
1Y
+3.0%
From 52W high
−35.6%
From 52W low
+49.1%
$22
$52
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MAZE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Maze Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
31/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
74
Value
60
Revisions
57
Quality
42
Volatility
40
Accruals
38
Size
36
Growth
30
Issuance
8

Momentum (74): The shares have been drifting up relative to others.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MAZE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MAZE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120Jan 26Apr 26Jul 26Oct 26MAZEHigh $110Median $55Low $46

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $46Median $55High $110

The green dot is the last close — the median target sits +64.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Oct 2026Canaccord GenuityInitiatesBuy$75
24 Sept 2026HC Wainwright & Co.ReiteratesBuy—
24 Sept 2026HC Wainwright & Co.ReiteratesBuy$110
23 Sept 2026CitigroupInitiatesBuy—
23 Sept 2026CitigroupInitiatesBuy$50
23 Sept 2026WedbushReiteratesOutperform$48
23 Sept 2026WedbushReiteratesOutperform—
22 Sept 2026BTIGReiteratesBuy$46
22 Sept 2026BTIGReiteratesBuy—
12 Aug 2026BTIGReiteratesBuy—
12 Aug 2026BTIGReiteratesBuy$46
14 Apr 2026Truist SecuritiesMaintainsBuy$68 → $64
14 Apr 2026Truist SecuritiesMaintainsBuy—
31 Mar 2026JP MorganMaintainsOverweight—
25 Mar 2026BTIGReiteratesBuy—
25 Mar 2026HC Wainwright & Co.MaintainsBuy—
18 Mar 2026Truist SecuritiesInitiatesBuy—
16 Mar 2026WedbushMaintainsOutperform—
10 Mar 2026MizuhoInitiatesOutperform—
9 Mar 2026BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MAZE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MAZE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Maze Therapeutics, Inc. returned +3.0% against +14.8% for the S&P 500, dividends included.

MAZE vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Jan 26Apr 26Jul 26Oct 26MAZES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MAZE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Maze Therapeutics, Inc. (MAZE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
189.5×

Cheaper than 3% of US stocks

Price / sales
92.7×

Cheaper than 4% of US stocks

Price / book
4.1×

Cheaper than 23% of US stocks

EV / EBITDA
−10.0×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−728.1%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−37.3%

Higher than 25% of US stocks

Return on assets
−21.8%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Maze Therapeutics, Inc. (MAZE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Maze Therapeutics, Inc. has a market value of $1.8B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $20.0M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$133.6M, a −668.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.52.

  • Free cash flow in the twelve months to 30 June 2026: −$106.8M.

  • Shares outstanding: 55.5M.

  • Trailing P/E: 189.5×; forward P/E: −10.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Maze Therapeutics, Inc. employs 141 people — $142K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

MAZE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MAZEMaze Therapeutics, Inc.$1.8B31
SLSSELLAS Life Sciences Group, Inc.$1.8B58
AGIOAgios Pharmaceuticals, Inc.$1.9B65
BRVEBraveheart Bio, Inc.$1.8B1
PGENPrecigen, Inc.$1.8B77
GENBGenerate Biomedicines, Inc.$1.8B1
ZBIOZenas BioPharma, Inc.$1.8B20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Maze Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MAZE news & analysis

Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know

Zacks Investment Research · 4 Nov 2026positive

Zacks Investment Research reports that Wall Street analysts’ average price target implies a potential 93.9% upside for Maze Therapeutics (MAZE). It notes that the usefulness of this metric is questionable, while earnings estimate revisions have trended positively.

Why it matters — MAZE watchers may note the analyst target and positive earnings estimate revision trend, alongside the source’s caveat about price-target effectiveness.

Maze Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewsWire · 3 Nov 2026neutral

Maze Therapeutics announced that CEO Jason Coloma will participate in three upcoming investor conferences.

Why it matters — The announcement gives MAZE watchers notice of upcoming opportunities to hear from the company's chief executive.

What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock

Zacks Investment Research · 19 Oct 2026positive

Zacks Investment Research upgraded Maze Therapeutics, Inc. to Zacks Rank #2 (Buy), citing growing optimism about the company’s earnings prospects. The excerpt says this might drive the stock higher in the near term.

Why it matters — The Zacks upgrade and its earnings-prospect rationale are relevant to MAZE watchers tracking analyst assessments.

How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%

Zacks Investment Research · 19 Oct 2026positive

Zacks reports that analysts’ average price targets imply 123.4% potential upside for Maze Therapeutics (MAZE). The excerpt notes that the metric’s effectiveness is questionable and that positive earnings estimate revisions may translate into upside.

Why it matters — MAZE watchers may note the reported analyst targets and positive estimate-revision trend, alongside the stated caveat about the metric’s reliability.

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

GlobeNewsWire · 6 Oct 2026positive

Maze Therapeutics said it will present data from its MZE829 and MZE782 programs at ASN Kidney Week 2026. The oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829, while two posters will cover preclinical research on SLC6A19 inhibition.

Why it matters — The presentations will provide updates on research supporting Maze’s kidney-disease programs.

FAQ

Frequently asked questions about MAZE stock

What is the MAZE stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Maze Therapeutics, Inc. have a median 12-month price target of $55, with estimates ranging from $46 to $110. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MAZE stock a buy right now?

Of the 14 analysts covering Maze Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Maze Therapeutics, Inc. 31 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MAZE?

As at 4 Nov 2026, Maze Therapeutics, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (74 of 100).

Will MAZE stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +64.8% from the last close, and Ticker Nerd's factor model ranks Maze Therapeutics, Inc. 31 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MAZE stock forecast for 2030?

No analyst covering Maze Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MAZE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $110 over the next 12 months.

How has MAZE stock performed over the past year?

Maze Therapeutics, Inc. returned +3.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Maze Therapeutics, Inc. do?

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney, cardiovascular, and related metabolic diseases, including obesity.

What is the latest news on MAZE?

The most recent item we track (Zacks Investment Research, 4 Nov 2026): "Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know". Zacks Investment Research reports that Wall Street analysts’ average price target implies a potential 93.9% upside for Maze Therapeutics (MAZE). It notes that the usefulness of this metric is questionable, while earnings estimate revisions have trended positively.

Company

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney, cardiovascular, and related metabolic diseases, including obesity. The company uses its human genetics-driven Compass platform to identify disease-linked genetic variants and translate those insights into targeted drug candidates. Its current pipeline includes oral programs aimed at genetically defined kidney disorders, reflecting a strategy centered on precision medicine and biologically validated pathways. Maze Therapeutics operates from South San Francisco, California, and is positioned within the broader biotechnology sector as a developer of novel therapies for patients with renal and metabolic conditions.

CEO Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. · 141 employees · United States · https://www.mazetx.com